Wintergerst, Maximilian W. M.
Merten, Nicholas R.
Berger, Moritz
Terheyden, Jan H.
Overbeck, Lennart J.
Schmid, Matthias
Holz, Frank G.
Finger, Robert P.
Funding for this research was provided by:
BONFOR GEROK Program (O-137.0228)
Ernst und Berta Grimmke Stiftung (3/22)
Else Kröner-Fresenius-Stiftung (EKFS/GSO 16)
Universitätsklinikum Bonn
Article History
Received: 19 May 2023
Accepted: 13 December 2023
First Online: 5 February 2024
Competing interests
: Maximilian W.M. Wintergerst: ASKIN & CO GmbH (recipient), Berlin-Chemie AG (recipient, financial support), CenterVue SpA (financial support), Carl Zeiss Meditec (financial support), D-Eye Srl (financial support), DigiSight Technologies (recipient, financial support), Eyenuk, Inc. (financial support), glaucare GmbH (owner, consultant), Heine Optotechnik GmbH (consultant, recipient, financial support), Heidelberg Engineering (recipient, financial support), Novartis Pharma GmbH (recipient, financial support), Optos (financial support); Nicholas R. Merten: No financial disclosures; Moritz Berger: No financial disclosures; Jan H. Terheyden: Heidelberg Engineering (Funding), Optos (Funding), Zeiss (Funding), CenterVue (Funding), Novartis (Recipient), Okko (Recipient); Lennart Overbeck: No financial disclosures; Matthias Schmid: No financial disclosures; Frank G. Holz: personal fees from Acucela, Apellis, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, Roche/Genentech, Geuder, Graybug, Gyroscope, Heidelberg Engineering, IvericBio, Kanghong, LinBioscience, Novartis, Oxurion, Pixium Vision, Oxurion, Stealth BioTherapeutics, and Zeiss. Grants from Allergan, Apellis, Bayer, Bioeq/Formycon, CenterVue, Ellex, Roche/Genentech, Geuder, Heidelberg Engineering, IvericBio, Kanghong, NightStarX, Novartis, Optos, Pixium Vision, and Zeiss; Robert P. Finger: Bayer (Consultant), Ellex (Consultant), Novartis (Consultant), Novartis (Funding), Ophtea (Consultant), Alimera (Consultant), Santhera (Consultant), Roche/Genentech (Consultant), CentreVue (Funding), Zeiss (Funding).